United Biologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

United Biologics operates in the niche but essential segment of providing high-fidelity silicone anatomical models for the medical device industry. Its core value proposition is a combination of over 22 years of collective experience, proprietary material science (AngioClear™), and the ability to deliver both standard and highly customized patient-specific models. The company generates revenue by selling these physical models and related accessories as services to support device development, training, and marketing, positioning itself as a key enabler for non-invasive procedural advancement.

AntibodiesBiologics

Technology Platform

Proprietary AngioClear™ silicone technology for creating optically clear, flexible, anatomically representative vascular models. Capabilities include standard and patient-specific customization based on anatomical references.

Opportunities

Growth is driven by the expanding global medical device market and increasing need for realistic training and testing tools for minimally invasive procedures.

The trend towards personalized medicine creates further opportunity for its patient-specific model customization service.

Risk Factors

Key risks include dependence on medical device company budgets, potential disruption from advanced digital/virtual simulation technologies, and competition from other model manufacturers that could pressure pricing and margins.

Competitive Landscape

United Biologics competes in the anatomical model segment against other specialized silicone model manufacturers and broader medical simulation companies. Its differentiation is based on its proprietary AngioClear™ material, deep industry experience, and strong customization capabilities for the medical device sector.

More companies in Diagnostics & Precision Medicine →More companies in United States →